false
0002030617
0002030617
2026-10-07
2026-10-07
FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
--12-31
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 7, 2026
Picard Medical, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-42801
|
|
86-3212894
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
1992 E Silverlake
Tucson AZ, 85713
|
|
(Address of principal executive offices, including zip code)
|
Registrant’s telephone number, including area code: (520) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
PMI
|
|
The NYSE American, LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 7, 2026, the Board of Directors (the “Board”) of Picard Medical Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws (as amended from time to time, the “Amended and Restated Bylaws”), effective immediately. The Amendment amends Section 9 of the Amended and Restated Bylaws to decrease the quorum required for a meeting of the Company's stockholders. Specifically, the quorum requirement was reduced from a majority of the voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote, to thirty-three and one-third percent (33 1/3%) of the voting power of such shares.
This Amendment complies with the minimum quorum requirements of Section 216 of the Delaware General Corporation Law and Section 123 of the NYSE American Company Guide.
The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
|
Exhibit No.
|
|
Description
|
|
3.1
|
|
Amendment to the Amended and Restated Bylaws of Picard Medical Inc., effective October 7, 2026. |
| 104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Picard Medical, Inc. |
| |
|
|
By: |
/s/ Georgina Smith
|
| |
Name:
|
Georgina Smith
|
| |
Title: |
Chief Accounting Officer
|
Dated: October 13, 2026
